Federal Order Moves Medical Marijuana to Schedule III, Expanding 13 Areas of Cannabis Law
Updated
Updated · The National Law Review · Jun 23
Federal Order Moves Medical Marijuana to Schedule III, Expanding 13 Areas of Cannabis Law
3 articles · Updated · The National Law Review · Jun 23
Summary
A federal order shifted DEA-approved cannabis medications and state-licensed medical marijuana from Schedule I to Schedule III, redrawing the legal framework cannabis lawyers must advise on.
Schedule III status reaches far beyond criminal law into tax, banking, capital markets, advertising, intellectual property, clinical research, employment and interstate commerce, expanding rather than simplifying the field.
Section 280E relief for licensed medical operators is one of the biggest practical gains, but the report says benefits are not automatic because clients still face DEA registration deadlines and compliance requirements.
Adult-use marijuana remains under Schedule I, leaving lawyers to distinguish sharply between medical and recreational clients as favorable headlines trigger more inquiries based on the mistaken view that cannabis is now broadly legal.
The change shifts uncertainty rather than ending it, raising new questions on commerce, patient care and related sectors such as psychedelics while keeping cannabis law a fast-moving specialty.
Cannabis rescheduling brings tax relief but also new federal rules. Is this a net gain or a hidden trap for businesses?
As federal policy on cannabis and psychedelics shifts, what new medical treatments and legal battles are on the horizon?
With medical marijuana now federally lawful, can states still block cannabis products from crossing their borders?
Marijuana Moves to Schedule III: 2026 Federal Policy Change, Legal Challenges, and Industry Implications
Overview
The federal approach to cannabis is changing, with the DEA set to hold a key hearing on June 29, 2026, following a process started by the Biden administration in 2022. This hearing will address the proposed move of cannabis from Schedule I to Schedule III, which would mark the first broad federal recognition of its medical use. While some FDA-approved and state-licensed marijuana products have already been rescheduled, the upcoming hearing aims to tackle wider policy and regulatory questions. However, legal challenges and unresolved tax and business issues mean the path forward remains uncertain for the cannabis industry.